Product Program year 2025 Source: CMS Open Payments

Itovebi

Biological BioOncology

NDC 50242-084-01

Open in the dashboard

General payments

$359,844

4,430 payments

Research payments

$5,948,006

688 payments

Through program year 2025, $359,844 in general payments and $5,948,006 in research payments were reported against Itovebi (BioOncology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Amount Payments
2025 General $272,613 3,129
2025 Research $4,607,512 435
2024 General $87,231 1,301
2024 Research $1,340,495 253

Breakdown

Who paid General payments · program years 2024–2025
  1. Genentech USA, Inc. $297,493 4,228 payments
  2. Genentech, Inc. $55,791 201 payments
  3. Hoffmann-La Roche Limited $6,560 1 payment
Top recipients General payments · program year 2025
  1. Cleveland Clinic Hospital Teaching hospital · OH $54,000 20% · 2 payments
  2. Ut Md Anderson Cancer Center Teaching hospital · TX $21,600 8% · 3 payments
  3. Univ Of Mi Hospitals & Hlth Ctrs Teaching hospital · MI $14,000 5% · 2 payments
  4. Komal Jhaveri Medical Oncology · New York, NY $8,351 3% · 4 payments
  5. Univ Of Missouri Health Care Teaching hospital · MO $8,200 3% · 3 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Hematology & Oncology Internal Medicine $43,563 34% · 800 practitioners
  2. Medical Oncology Internal Medicine $36,592 28% · 223 practitioners
  3. Nurse Practitioner, Family Nurse Practitioner $12,854 10% · 370 practitioners
  4. Internal Medicine $6,756 5% · 54 practitioners
  5. Nurse Practitioner $5,438 4% · 190 practitioners

The top 5 of 74 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Ohio $56,818 21% · 91 recipients
  2. California $33,104 12% · 209 recipients
  3. Texas $30,965 11% · 130 recipients
  4. New York $27,011 10% · 136 recipients
  5. Florida $24,813 9% · 234 recipients

The top 5 of 51 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

4,430 general · 688 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record